We are live on ! Find out more
NRIX icon

Nurix Therapeutics

196 hedge funds and large institutions have $1.81B invested in Nurix Therapeutics in 2026 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 67 increasing their positions, 43 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,567% more call options, than puts

Call options by funds: $3.95M | Put options by funds: $237K

88% more capital inflows, than outflows

Capital inflows: $330M | Capital outflows: $176M

56% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 43

52% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 29

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

7% more funds holding

Funds holding: 184 → 196 (+12)

4.74% more ownership

Funds ownership: 148.36% → 153.1% (+4.7%)

Holders
196
Holders Change
+12
Holders Change %
+6.52%
% of All Funds
2.38%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.06%
New
44
Increased
67
Reduced
43
Closed
29
Calls
$3.95​M
Puts
$237​K
Net Calls
+$3.71​M
Net Calls Change
+$597​K

NRIX Hedge Fund Activity: Q1 2026 in Review

196 of the 8,244 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q1 2026, worth a combined $1.81B — down 16% from $2.15B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new NRIX positions and 29 closed out — a net gain of 15 holders — while 67 added to existing stakes and 43 trimmed.

The largest buyer was Vestal Point Capital, adding an estimated $30M. The largest seller was Point72 Asset Management, cutting an estimated $45.8M.

  • 196 institutional investors held Nurix Therapeutics (NRIX) as of Q1 2026, up from 184 in Q4 2025.
  • Funds reported $1.81B of Nurix Therapeutics stock for Q1 2026, down 16% quarter-over-quarter.
  • 44 funds opened new Nurix Therapeutics positions in Q1 2026 and 29 closed out, a net change of +15 holders.
  • The largest Nurix Therapeutics buyer in Q1 2026 was Vestal Point Capital, an estimated $30M added.
  • The largest Nurix Therapeutics seller in Q1 2026 was Point72 Asset Management, an estimated $45.8M sold.

Based on aggregated 13F filings for Q1 2026.